The results of DINASTIYA study - Diabeton MB: the observational program among the patients with type 2 diabetes mellitus under conditions of routine clinical practice

Cover Page

Abstract


The aim of the DINASTIYA study (the name of this study is the acronym composed of the selected letters from the Russian title: "DIabeton MB - Nablyudatel'naya programma sredi patsientov c Sakharnym diabeTom 2 tipa v uslovIYAkh rutinnoy praktiki") was to estimate the possibility of achieving the targeted parameters of glycemic control by means of the step by step increase of diabeton MB dose and to evaluate the safety of this therapy under conditions of routine clinical practice. Materials and methods: The program involved 2213 patients with poorly controlled type 2 diabetes mellitus who had been treated with diabeton MB during the preceding period (30-90 mg/day in the form of monotherapy or in combination with the maximum tolerated dose of metformin). The dose of diabeton MB was titrated under control of glycemia during 3 months. The combined treatment including metformin was given to 70% of the patients. The average daily dose of diabeton MB by the end of the study was 90.9 mg. As many as 70% of the petients received diabeton MB at a daily dose of 90-120 mg. Results: The statistically significant reduction of the fasting blood glucose (FG) level from 8.3±1.6 mmol/l to 6.2±0.9 mmol/l and postprandial glycemia (PPG) from 10.5±2.1 mmol/l to 7.6±1.0 mmol/l was documented within 3 month after the onset of therapy. The targeted FG and PPG levels (<6.5 mmol/l and <8.0 mmol/l) were achieved in 68.9% and 71.5% of the patients respectively. Simultaneously, the body weight decreased (by 1 kg on the average) and arterial pressure fell down (SAP - 8.4 and DAP - 3.9 mm HG respectively). Conclusion: The strategy of management of type 2 diabetes mellitus based on the step by step increase of the dose of diabeton MB allows the targeted parameters of glycemic control to be achieved in combination with the good tolerability of the treatment and the low risk of development of hypoglycemia.

M V Shestakova

O K Vikulova

Email: Olga-vikulova-1973@yandex.ru

D A Avaliani

S N Avdeeva

G P Aĭdinian

L P Akishina

N V Aleĭnikova

E G Aleksandrova

O V Aleksandrova

  1. Patel A., MacMahon S., Chalmers J., Neal B. et al. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
  2. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C. et al. The Action to Control Cardiovascular Risk in Diabetes Study Group: effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
  3. Duckworth W., Abraira C., Mortiz T., Reda D. et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
  4. Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б., Галстян Г.Р., Майоров А.Ю., Мкртумян А.М., Петунина Н.А., Сухарева О.Ю. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахарснижающей терапии сахарного диабета 2-го типа. Сахарный диабет 2011; 4: 53: 6-16.
  5. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012. doi: 10.2337/dc12-0413
  6. International Diabetes Federation. The IDF Clinical guidelines and Position Statements 2012, www.idf.org.
  7. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten G.E.H.M., Shaw K.M. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34: 535-542.
  8. Drouin I.P., Standl E. For the Diamicron MR Study Group. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabet Obesity Metabol 2004; 6: 414-421.
  9. Zoungas S., Chalmers J., Kengne A.P., Pillai A., Billot L., de Galan B., Marre M., Neal B., Harrap S., Poulter N., Patel A. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diab Res Clin Pract 2010 89:126-133. doi: 10.1016/j.diabres.2010.05.012
  10. Шестакова М.В., Викулова О.К. Результаты открытой наблюдательной программы DIAMOND. Сахарный диабет 2011; 3: 52: 96-102.
  11. Tessier D., Dawson K., Tetrault J.P., Bravo G., Meneilly G.S. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994; 11: 974-980.
  12. Veitch P.C., Clifton-Bligh R.J. Long-acting sulfonylureas - long-acting gypoglycaemia. Med J Aust 2004; 180: 84-85.

Views

Abstract - 1588

Cited-By


PlumX

Dimensions


Copyright (c) 2012 Shestakova M.V., Vikulova O.K., Avaliani D.A., Avdeeva S.N., Aĭdinian G.P., Akishina L.P., Aleĭnikova N.V., Aleksandrova E.G., Aleksandrova O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies